Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2011-08-30
2011-08-30
Hayes, Robert C (Department: 1649)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
Reexamination Certificate
active
08008465
ABSTRACT:
The present invention relates to a toxin comprising a modified light chain of a botulinum toxin type E, wherein the modified light chain comprises amino acid sequence PFVNKQFN (SEQ ID NO: 120) at the N-terminus, and amino acid sequence xExxxLL (SEQ ID NO: 112) at the C-terminus, wherein x is any amino acid.
REFERENCES:
patent: 4932936 (1990-06-01), Dykstra et al.
patent: 5053005 (1991-10-01), Borodic
patent: 5437291 (1995-08-01), Pasricha et al.
patent: 5670484 (1997-09-01), Binder
patent: 5714468 (1998-02-01), Binder
patent: 5714986 (1998-02-01), Dao
patent: 5721215 (1998-02-01), Aoki et al.
patent: 5766605 (1998-06-01), Sanders et al.
patent: 5939070 (1999-08-01), Johnson et al.
patent: 5989545 (1999-11-01), Foster et al.
patent: 6063768 (2000-05-01), First
patent: 6113915 (2000-09-01), Aoki et al.
patent: 6139845 (2000-10-01), Donovan
patent: 6143306 (2000-11-01), Donovan
patent: 6265379 (2001-07-01), Donovan
patent: 6299893 (2001-10-01), Schwartz et al.
patent: 6306403 (2001-10-01), Donovan
patent: 6306423 (2001-10-01), Donovan
patent: 6312708 (2001-11-01), Donovan
patent: 6328977 (2001-12-01), Donovan
patent: 6358513 (2002-03-01), Voet et al.
patent: 6365164 (2002-04-01), Schmidt
patent: 6395277 (2002-05-01), Graham
patent: 6423319 (2002-07-01), Brooks et al.
patent: 6458365 (2002-10-01), Aoki et al.
patent: 6464986 (2002-10-01), Aoki et al.
patent: 6903187 (2005-06-01), Steward et al.
patent: 7393925 (2008-07-01), Steward et al.
patent: 7491799 (2009-02-01), Fernandez-Salas
patent: 7534863 (2009-05-01), Fernandez-Salas
patent: 2003/0027752 (2003-02-01), Steward et al.
patent: 2003/0219462 (2003-11-01), Steward et al.
patent: 2008/0177037 (2008-07-01), Steward et al.
patent: 2008/0177041 (2008-07-01), Steward et al.
patent: 2008/0177042 (2008-07-01), Steward et al.
patent: 2008/0194797 (2008-08-01), Steward et al.
patent: 2008/0214781 (2008-09-01), Steward et al.
patent: 2009/0118475 (2009-05-01), Fernandaz-Salas
patent: 2009/0202591 (2009-08-01), Fernandez-Salas
patent: WO94/15629 (1994-07-01), None
patent: WO 96/39166 (1996-12-01), None
patent: WO 97/32599 (1997-09-01), None
patent: WO98/08540 (1998-03-01), None
patent: WO 00/05252 (2000-02-01), None
patent: WO 02/08268 (2002-01-01), None
Fernandez-Salas, E., et al.,Plasma membrane localization signals in the light chain of botulinum neurotoxin serotype A, Society for Neuroscience Abstract Viewer and Itinerary Planner, vol. 2003; pp. Abstract No. 9.2.
Foran, Patrick G., et al.,Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct durations of inhibition of exocytosis in central neurons, Journal of Biological Chemistry, vol. 278, No. 2, Jan. 10, 2003, pp. 1363-1371.
Wang Xingmin, et al.,Genetic analysis of type E botulinum toxin-producing Clostridium butyricum strains, Applied and Environmental Microbiology, vol. 66, No. 11, Nov. 2000, pp. 4992-4997.
Fernandez-Salas, E., et al.,Plasma membrane localization signals in the light chain of botulinum neurotoxin, Proceedings of the National Academy of Sciences of the United States of America, Mar. 2, 2004, vol. 101, No. 9, pp. 3208-3213.
Adenis, et al., J. Fr. Ophthamol. (1990) 13:259-264, English Abstract only.
Binz, et al., J. Biol. Chem. (1990) 265:9153-9158.
Blitzer, et al., Ann. Otol. Rhinol Laryngol. (1985) 94:591-594.
Brin, et al., Advances in Neurology, vol. 50: Dystonia 2 (1988), pp. 599-608.
Cohn, et al., Neurology (1987) 37 (3 Supp. 1):123-124, Abstract only.
Darsow, et al., J. Cell Biol. (1998) 142:913-922.
Elston, et al., Br. J. Opthamol. (1985) 69:718-724.
Elston, et al., Br. J. Opthamol. (1985) 69:891-896.
Galli, et al., Mol. Bio. Cell (1998) 9:1437-1448.
Park and Simpson, “Inhalational poisoning by botulinium toxin and inhalation vaccination with its heavy-chain component,” Infect. Immun. (2003) 71:1147-1154.
Atassi and Oshima, “Structure, activity and immune (T and B cell) recognition of botulinum neurotoxins,” Crit. Rev. Immunol. (1999) 19:219-260.
Marchese Ragona, et al., “Management of parotid sialocele with botulinum toxin,” The Laryngoscope (1999) 109:1344-1346.
Wiegand, et al., “125-I labelled botulinum A neurotoxin: pharmacokinetics in cats after intramuscular injection,” Naunyn-Schmiedeberg's Arch. Pharmacol. (1976) 292:161-165.
Habermann, “125-I labeled neurotoxin fromClostridium botulinumA: preparation, bindng to synaptosomes and ascent to the spinal cord,” Naunyn-Schmiedeberg's Arch. Pharmacol. (1974) 281:47-56.
Moyer, et al., “Botulinum Toxin Type B: Experimental and Clinical Experience,” in Therapy with Botlinum Toxin, Jankovic, ed., 1994, pp. 71-84.
Gonelle-Gispert, “SNAP-25a and -25b isoforms are both expressed in insulin secreting cells and can function in insulin secretion,” Biochem. J. (1999) 339:159-165.
International Conference on Botulinum Toxin: Basic Science and Clinical Therapeutics, Mov. Disord. (1995) 10:361-408.
Haberman, et al., “Tetanus toxin and botulinum A and C neurotoxins inhibit noradrenaline release from cultured mouse brain,” J. Neurochem. (1988) 51:522-527.
Sanchez-Prieto, et al., “Botulinum toxin A blocks glutamate exocytosis from guinea pig cerebral cortical synaptosomes,” Eur. J. Biochem. (1987) 165:675-681.
Pearce, “Pharmacologic characterization of botuinum toxin for basic science and medicine,” Toxicon, 35:1373-1412, (1997).
Zhou, et al., Biochemistry (1995) 34:15175-15181.
Shin, et al., J. Biol. Chem. (1991) 266:10658-10665.
Raciborska and Charlton, Can. J. Physiol. (1999) 77:679-688.
Erdal, et al., Arch. Pharmacol. (1995) 351:67-78.
Naumann, et al., Eur. J. Neurol. (1999) 6:S111-S115.
Keller, et al., FEBS Lett. (1999) 456:137-142.
Dietrich, et al., J. Cell. Biol. (1997) 138:271-281.
Geisler, et al., J. Biol. Chem. (1998) 273:21316-21323.
Tan, et al., J. Biol. Chem. (1998) 273:17351-17360.
Liu, et al., Trends Cell Biol. (1999) 9:356-363.
Cai and Singh, Biochemistry (2001) 40:4693.
Tikkanen, et al., Traffic (2000) 1:631-640.
Rapaport, et al., EMBO J. (1998) 17:2148-2155.
Cowles, et al., Cell (1997) 91:109-118.
Aoki, et al., J. Neurol. (2001) 248 (Supp 1):3-10.
Aoki, Toxicon. (2001) 12:1815-1820.
Thompson, et al., Eur. J. Biochem. (1990) 189:73.
Cenci Di Bello, et al., Eur. J. Biochem. (1994) 219:161-169.
Arnon, et al., “Botulinum toxin as a biological weapon: medical and public health management,” JAMA (2001) 285:1059-1070.
Eswaramoorthy, et al., “A novel mechanism forClostridium botulinumneurotoxin inhibition,” Biochemistry (2002)41:9795-9802.
Aoki, et al., “Is the light chain subcellular localization an important factor for Botulinum neurotoxin duration of action?,” Naunyn Schmiedebergs Arch. Pharmacol. (2002) 365 (Suppl 2):R10.
Fernandez-Salas, et al., “Localization of BoNT light chains in neuronal and non-neuronal cell lines, implications for the duration of action of the different serotypes,” Naunyn Schmiedebergs Arch. Pharmacol. (2002) 365 (Suppl 2):R19.
Steward, et al., “BoNT/A light chain and the dileucine motif: potential implications for light chain localization and neurotoxin duration of action,” Naunyn Schmiedebergs Arch. Pharmacol. (2002) 365 (Suppl 2):R44.
Jancovic, et al., Neurology (1987) 37:616-623.
Kadkhodayan, et al., Protein Express. Purif. (2000) 19:125-130.
Kozaki, et al., J. Med. Sci. Biol. (1981) 34:61-68.
Lacy, et al., Nat. Struct. Biol. (1998) 5:898-902.
Li, et al., Biochemistry (1994) 33:7014-7020.
Maisey, et al., Eur. J. Biochem. (1988) 177:683-691.
Martinez-Arca, et al., J. Cell Biol. (2000) 149:889-899.
Milton, et al., Biochemistry (1992) 31:8799-8809.
Minton, Molecular genetics of Clostridial Neurotoxins, Montecucco C. (Ed.) Clostridial Neurotoxins in the molecular pathogenesis of tetanus and botulism, Berlin; NY: Springer Verlag, 1995, pp. 161-194.
Peden, et al., J. Biol. Chem. (2001) 276:49183-49187.
Swain, et al., Peptide Res. (1993) 6:147-154.
Dong, et al., PNAS, 101(41): 14701-14706, 2004.
Fe
Aoki K. Roger
Fernandez-Salas Ester
Herrington Todd
Steward Lance E.
Abel Kenton
Allergan Inc.
Condino Debra
Hayes Robert C
LandOfFree
Nucleic acids encoding chimera botulinum toxin type E does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nucleic acids encoding chimera botulinum toxin type E, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleic acids encoding chimera botulinum toxin type E will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2764611